文献速递心外重症与机械循环支持

左心室辅助装置植入后急性肾损伤与1年死亡率

Acute kidney injury and 1-year mortality after left ventricular assist device implantation.
PubMed 文献 · J Heart Lung Transplant · 2017-11-06

该多中心回顾性队列研究纳入241例连续流左心室辅助装置(LVAD)植入患者,采用KDIGO标准定义急性肾损伤(AKI)。70%患者发生AKI,其中III期占16%;AKI分期越高,1年死亡率越高(无AKI 18.7%,III期51%),AKI≥II期与1年死亡独立相关。

要点

  • LVAD植入后AKI发生率高达70%,III期占16%。
  • AKI分期越高,1年死亡率越高,III期达51%。
  • AKI≥II期是1年死亡的独立危险因素(HR 2.2)。

核心结论

  • LVAD植入后AKI非常常见,更严重的AKI分期与更高的1年死亡率和肾功能损害相关。

研究设计与样本

  • 回顾性多中心队列研究,纳入241例年龄≥18岁接受LVAD植入的患者(91%为HeartMate II,9%为HeartWare)。

主要发现

  • 169例(70%)患者符合AKI标准,其中I期109例(45%)、II期22例(9%)、III期38例(16%)。
  • 无AKI及AKI I、II、III期的1年死亡率分别为18.7%、26.4%、23%和51%(log rank p=0.001)。
  • 多因素分析中,AKI≥II期与死亡独立相关(HR 2.2,95%CI 1.1-4.5,p=0.027)。
  • AKI≥II期与1年时更差的肾功能独立相关(β=-7.4,95%CI -12.6至-2.1,p<0.01)。

关键数值与推荐

  • AKI定义采用KDIGO标准。
  • 术前需要正性肌力药物支持和术前存在慢性肾脏病(eGFR<30 ml/min/1.73 m2)与AKI发生及严重程度独立相关。

临床怎么用

  • LVAD植入后应密切监测肾功能,按KDIGO标准识别AKI分期。
  • 对术前需正性肌力药物支持或eGFR<30 ml/min/1.73 m2的高危患者加强肾脏保护。
  • 发生AKI≥II期提示1年死亡风险增加,需强化随访和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on the consequences of acute kidney injury (AKI) after continuous-flow left ventricle assist device (LVAD) implantation are scarce and inconsistent. In this study, we evaluated the incidence, predictors and the impact of AKI on mortality and renal function in the first year after LVAD implantation. METHODS: A retrospective, multicenter cohort study was conducted, including all patients (age ≥18 years) undergoing LVAD implantation (91% with a HeartMate II device and 9% with a HeartWare device). The definition proposed by the Kidney Disease Improving Global Outcome (KDIGO) criteria was used to define AKI. RESULTS: Overall, 241 patients (mean age 52.4 ± 12.9 years, 76% males) were included in the study. AKI criteria were met in 169 (70%) patients, of whom 109 (45%) were in AKI Stage I, 22 (9%) in Stage II and 38 (16%) in Stage III. Two factors, the need for pre-operative inotropic support and pre-existent chronic kidney disease Stage ≤II (estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m2), were independently associated with the development of AKI and the severity of AKI stages. One-year mortality rates in patients without AKI and AKI Stages I, II and III were 18.7%, 26.4%, 23%, and 51%, respectively (log rank, p = 0.001). In the multivariable analysis, AKI Stage ≥II was independently associated with mortality (hazard ratio 2.2 [95% confidence interval 1.1 to 4.5], p = 0.027) and worse renal function (β = -7.4 [95% confidence interval -12.6 to -2.1], p < 0.01) at 1 year. CONCLUSION: AKI is highly frequent after LVAD implantation. More severe AKI stages are associated with higher mortality rates and impaired renal function at 1 year after LVAD implantation.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Muslem R, Caliskan K, Akin S, et al. Acute kidney injury and 1-year mortality after left ventricular assist device implantation. J Heart Lung Transplant. 2017. PMID: 29174532. doi:10.1016/j.healun.2017.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。